STOCK TITAN

Tango Therapeutics' Crystal Adam sells 5,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Tango Therapeutics, Inc. (TNGX) reported that its President, R&D, Crystal Adam exercised options to acquire 5,000 common shares at $2.91 per share on November 11, 2026, then sold 5,000 common shares at a weighted average price of $25.00 per share. The sale prices ranged from $25.00 to $25.9999 per share.

The exercise and sale were made under a Rule 10b5-1 trading plan adopted on June 10, 2026. The reported option position following the exercise was 308,090 shares.

Insider Crystal Adam
Role President, R&D
Sold 5,000 shs ($125K)
Approx. gross sale proceeds $125K
Approx. exercise cost $15K
Approx. pre-tax spread $110K
Share of Position Sold 4.1%
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1, F3 5,000 $0.00 $0.00
Exercise Common Stock F1 5,000 $2.91 $15K
Sale Common Stock F1, F2 5,000 $25.00 $125K
Holdings After Transaction: Stock Option (Right to Buy) — 308,090 options (Direct); Common Stock — 115,743 shares (Direct)
Holdings Before and After: Stock Option (Right to Buy), 313,090 to 308,090 options (Direct); Common Stock, 115,743 to 115,743 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (3)
  1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026.
  2. F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $25.00 to $25.9999 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  3. F3. This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter.
Options exercised 5,000 options November 11, 2026
Exercise price $2.91 per share November 11, 2026 option exercise
Common shares sold 5,000 shares November 11, 2026
Weighted average sale price $25.00 per share November 11, 2026 sale
Sale price range $25.00 to $25.9999 per share Prices for the shares sold on November 11, 2026
Option position after exercise 308,090 shares Reported following the November 11, 2026 transaction
Rule 10b5-1 trading plan regulatory
"pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price per share financial
"Represents the weighted average sales price per share"
vest and become exercisable financial
"shall vest and become exercisable over a four-year period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TNGX shares did Crystal Adam sell and at what price?

Crystal Adam sold 5,000 common shares at a weighted average of $25.00 per share on November 11, 2026. The shares sold at prices ranging from $25.00 to $25.9999 per share. The sale was made under a Rule 10b5-1 trading plan adopted on June 10, 2026.

How many TNGX options did Crystal Adam report after the exercise?

The reported option position following the November 11, 2026 exercise was 308,090 shares.

How did Crystal Adam's TNGX options vest?

The options vest and become exercisable over four years, with 25% vesting on January 1, 2026 and the remaining option shares vesting in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Crystal Adam

(Last)(First)(Middle)
C/O TANGO THERAPEUTICS, INC.
201 BROOKLINE AVE., SUITE 901

(Street)
BOSTON MASSACHUSETTS 02215

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President, R&D
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/11/2026M(1)5,000A$2.91120,743D
Common Stock11/11/2026S(1)5,000D$25(2)115,743D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$2.9111/11/2026M(1)5,000 (3)02/03/2035Common Stock5,000$0308,090D
Explanation of Responses:
1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026.
2. Represents the weighted average sales price per share. The shares sold at prices ranging from $25.00 to $25.9999 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter.
/s/ Julie Fogarty, as attorney-in-fact11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading